Biogen Scores a Big Win for ADUHELM™, But the Path Ahead Isn’t Easy!
Biogen, Inc. (NASDAQ: BIIB) ADUHELM™ (aducanumab-avwa), scored an approval from the U.S. Food and Drug Administration (FDA), to become the first drug approved after 2003 for the treatment of Alzheimer’s disease, which specifically addresses the underlying cause of the disease, by removing amyloid beta from...
